Become a logicalchat Member

Latest Post

Best stock to purchase today under $50 in 2025

Stock Analysis: Best Stock to Purchase Today Under $50 in 2025 – CAE Inc. (CAE) For investors searching for the best stock to purchase today...

Your story starts here. Sign up and let's connect in ways that truly matter!

HomeUncategorizedUpgrades and Downgrades: Micron, Magnite, and GoodRx Receives Upgrade; Hims Hers Health...

Upgrades and Downgrades: Micron, Magnite, and GoodRx Receives Upgrade; Hims Hers Health Faces Downgrade.

Upgrades and Downgrades; Wall Street analysts have upgraded Micron, Magnite, and GoodRx Holdings, while downgrading Him Hers Health.

Micron

Morgan Stanley Upgrades Micron

  • Upgraded Micron to Equalweight
  • Sets $130 price target.

Morgan Stanley Acknowledges Missteps in Negative View of Micron

  • Acknowledges the misstep of maintaining a negative stance on Micron.
  • Acknowledges three key errors in their research report:
  • Overemphasis on recent losses.
  • Prediction of significant cash burn, financial losses, and book value erosion.
  • Overestimation of the significance of High Bandwidth Memory (HBM) in the narrative.
  • Acknowledges Micron’s robust 3e product, which propelled them into the winners’ camp during a phase when proximity to AI drove most of the alpha generation in the space.

Micron Stock Reaction:

  • Opened regular session at $127.30.
  • Closed at $129.00, 2.96% gain from prior day.

PENN Entertainment

Raymond James Coverage on PENN Entertainment

  • Started coverage on Tuesday.
  • Targeted $20 price.

PENN’s Q1 Q1 Performance and Outlook

  • PENN faced challenges in Q1 due to weather-influenced weakness in the land-based business, higher-than-expected losses in the digital sector, and a significant selloff due to management-related issues.
  • Despite setbacks, the core land-based gaming business remains robust, achieving record revenue and EBITDAR levels in 2023.
  • Raymond James’ positive stance on PENN’s stock is based on the belief that the market is undervaluing the digital business and the fair value for the land-based business is estimated to be north of $20 per share.
  • Despite challenges, Raymond James identifies value in the land-based operations and predicts the security is expected to appreciate or outperform the S&P 500 over the next 12-18 months.

Penn Entertainment Stock Reaction

  • Opened regular session at $16.39
  • Closed at $16.41
  • Gained 0.86% from prior day.

Hims Hers Health

Hims Hers Health

  • Downgraded to Neutral.
  • Price target: $20.

Citi’s HIMS Program and Market Analysis

  • Citi expresses encouragement for HIMS’ new program, despite potential regulatory and legal risks.
  • HIMS is partnering with a large 340B manufacturer producing Semaglutide, using API, processes, and expedients similar to Novo.
  • Despite a 20% stock increase since the announcement, HIMS has added approximately $760M of enterprise value on limited new information.
  • Citi downgrades HIMS from Buy/High Risk to Neutral/High Risk, awaiting further details on GLP-1 economics and durability.
  • Despite the downgrade, Citi remains attentive to HIMS’ future moves and market potential.

Hims & Hims Health Stock Reaction

  • Opened regular session at $16.90.
  • Closed at $16.17, 7.84% loss from prior day.

Goodrx Holdings Inc

RBC Capital Upgrades Goodrx Holdings Inc

  • Upgraded to Outperform
  • Targeted $10 price.

GDRX’s Growth Opportunities and RBC Capital’s Price Target

  • GDRX’s ISP and DC initiatives and MfgSolns business scaling offer growth opportunities.
  • The company has signed five PBMs and seven top-10 pharmacies, indicating a 3-year mid-teens+ EBITDA CAGR.
  • RBC Capital believes execution will re-rate GDRX’s current 10x ’25 EBITDA valuation to align with growth rate and 14x peer average.
  • Analysts have raised the price target to $10.

GoodRx Holdings Stock Reaction

  • Opened regular session at $7.74.
  • Closed at $7.24, 0.56% gain from prior day.

Magnite Inc

BofA Securities Upgrades Magnite Inc.

  • Upgraded to Buy.
  • Price target: $15.

RBC Upgrades MGNI

  • MGNI upgraded as premier supply-side technology solution in CTV advertising.
  • Sector expected to grow at mid-teens rate over medium term.
  • MGNI excels in automated ad execution.
  • MGNI recognized as preferred ad tech collaborator for buy-side entities and sell-side participants.
  • Leading-edge programmatic technology underscored by partnerships with Netflix and MediaOcean.
  • Combines an ad server and an SSP, serving as a hub for publishers’ programmatic frameworks.
  • Less susceptible to disintermediation than standalone SSPs.
  • Disney and Paramount’s insights indicate rapid shift towards programmatic methods.
  • Projections of 50% increase by end of 2024 within premium streaming services.
  • Analysts at RBC Capital view sustained market share growth for MGNI.
  • “Buy at BofA” implies a total return of at least 10%.

Stock Reaction:

  • Opened regular session at $12.03
  • Closed at $12.57
  • Gained 13.55% from prior day.

Must read book about investing – check here

Upgrades and Downgrades Upgrades and Downgrades Upgrades and Downgrades Upgrades and Downgrades

Related Post